

ASTRAZENECA  
ONCOLOGY  
EDUCATION

**Invitation**  
**Nordic - Baltic Masterclass**  
BRCA tumor testing

February, 28<sup>th</sup> 2017

AstraZeneca 



## In co-operation with:

Estrid Høgdall, Professor, Dr. Sc., Ph.d., Head of Molecular Unit, Herlev Hospital, University of Copenhagen, AstraZeneca arranges a Nordic Baltic Master Class

## Course Summary:

The course will focus on BRCA tumor testing in ovarian and breast cancer  
Topics covered will focus on BRCA1 & BRCA2 mutations  
Which patient's should we test?  
How to test BRCA?  
Who is going to prescribe the BRCA test?  
How should the genetic counselling process look like?  
What could become the future (somatic & germline testing)?

## Date and time:

Tuesday the 28th February 2017 at 9:30 to 16:30

## Meeting place:

Scandic Copenhagen, Vester Søgade 6, 1601 Copenhagen V

<https://www.scandichotels.com/hotels/denmark/copenhagen/scandic-copenhagen>

## Participants:

Healthcare professionals working within oncology, pathology, genetics and biochemistry

## Signing up for the course:

Before 15th February via email to [mette.sorensen@astrazeneca.com](mailto:mette.sorensen@astrazeneca.com)

Please state country, workplace, your name and telephone number. Numbers of seats limited. Final registration will be confirmed by AstraZeneca

AstraZeneca cannot reimburse your travel costs



## Program Tuesday the 28<sup>th</sup> February 2017

**9:30-10:00** Coffee

### ***Welcome and introduction***

#### **Why focus on BRCA1 and BRCA2 - How far are we?**

**10:00-10:15** *Estrid Høgdall, Professor, Dr. Sc., Ph.d., Head of Molecular Unit, Herlev Hospital, University of Copenhagen*

#### **Hereditary breast and ovarian cancer - Consequences for the patient and their family**

**10:15-10:45** *Anne-Marie Gerdes, Professor, Ph.d., Head of Genetic Clinic, Rigshospitalet, University of Copenhagen*

#### **Review of Danish guidelines in BRCA mutated Patients in breast cancer**

**10:45-11:15** *Bent Ejlersen, Prof. Ph.d., Head of DBCG, Dept. Of Oncology, Rigshospitalet, University of Copenhagen*

#### **Norwegian germline BRCA testing up-front at diagnosis on patients with breast cancer**

**11:15-11:45** *Lovise Mæhle, MD, Ph.d. Head of Hereditary cancer unit, Oslo University Hospital*

### ***Lunch 11:45 – 12:45***

#### **Review of Danish guidelines in BRCA mutated Patients in breast cancer**

**12:45-13:15** *Claus Høgdall, Professor Dr. Sc., Gynaecologic Clinic, Rigshospitalet, University of Copenhagen*

#### **Why do we need tumor testing in ovarian cancer and who should be tested**

**13:15-13:45** *Mansoor Mirza, Chief Oncologist, Dept. of Oncology, Rigshospitalet, University of Copenhagen*

#### **KIU – Women with reproductive cancers – Patient Association perspectives**

**13:45-14:15** *Birthe Lemley, President of KIU (Kræft I Underlivet)*

**Coffee 14:15 – 14:30**



**How do we test in blood? What are the technical issues?**

**14:30-15:00** *Mads Thomassen, Associate Professor, Molecular biologist, Ph.d., Human Genetics, Department of Clinical Research, Odense University Hospital*

**How do we test in tissue? What are the technical issues?**

**15:00-15:30** *Tim Svenstrup Poulsen, Molecular Biologist, Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen*

**Classification of variants and implications for testing tumor tissue for germline mutations**

**15:30-16:00** *Thomas Hansen Head Biochemist, Ph.d., Center of Genomic Medicine, Rigshospitalet, University of Copenhagen*

**Wrap-up and future demands for testing**

**16:00-16:30** *Estrid Høgdall, Professor, Dr., Sc., Ph.d., Head of Molecular Unit, Herlev Hospital*

# Yours sincerely

**Estrid Høgdall**

Professor, Dr., Sc., Ph.d.  
Head of Molecular Unit  
Herlev Hospital

**Mette Sørensen**

Strategic Account Manager  
AstraZeneca A/S  
Nordic-Baltic MC

**Per Barfod**

Nordic Diagnostic Manager  
AstraZeneca A/S  
Nordic-Baltic MC

**Ulla Jensen**

National Oncology Lead DK  
AstraZeneca A/S  
Nordic-Baltic MC

*Det er med AstraZenecas invitation og den relaterede økonomiske støtte ikke intentionen at fremkalde eller begunstige ordination af AstraZeneca lægemidler eller enhver anden uretmæssig handling som begunstiger AstraZeneca. Hvis du deltager i foranstaltninger eller afgørelser, der berører et AstraZeneca produkt eller brug (f.eks. registrering af et lægemiddel eller tilskud, udbud) inden for en rimelig frist efter at være blevet valgt som deltager / delegeret, bør du overveje ikke at deltage i disse foranstaltninger eller afgørelser, for at undgå enhver opfattelse af utilbørlig indflydelse.*

*Iflg. Reklamebekendtgørelsen må kun sundhedspersoner deltage i AstraZenecas efteruddannelsesarrangementer. Ved sundhedspersoner forstås læger, tandlæger, dyrlæger, farmaceuter, sygeplejersker, veterinær-sygeplejersker, farmakonomer, jordemødre, bioanalytikere, kliniske diætister, radiografer, social- og sundhedsassistenter og studerende inden for disse fag.*

*Når du tilmelder dig dette møde, indsamler AstraZeneca dine personoplysninger (fx navn, e-mail). Formålet med indsamlingen er at administrere og bekræfte din deltagelse i mødet. AstraZeneca opbevarer dine oplysninger i en periode på 6 måneder fra den dato, hvor mødet finder sted. Ved at kontakte os skriftligt, kan du anmode om kopi af de oplysninger, som AstraZeneca har om dig, og/eller anmode om korrektion af dine oplysninger. Ved at sende os dine oplysninger, accepterer du behandlingen af dine personoplysninger som beskrevet.*

*Arrangementet vil blive anmeldt til Etisk Nævn for Lægemiddelindustrien (ENLI), inden arrangementets afholdelse, og arrangementet er i sin eksisterende form og indhold forhåndsgodkendt af ENLI.*

ATLAS APPROVAL ID Number 1025907,011

AstraZeneca A/S, Nordic-Baltic MC, Arne Jacobsens Allé 13, DK-2300 Copenhagen S. [www.connectinhealth.dk](http://www.connectinhealth.dk)

